Low-dose tocilizumab is associated with improved outcome and a low risk of secondary infection in severe COVID-19 pneumonia.
İlhami CelikEsma Eryılmaz ErenAysin Kilinc-TokerDidem ErenMerve YıldızAzade KanatUlaş Serkan TopaloğluSeda GuzeldagMehmet KaraAysegul Ulu-KilicPublished in: International journal of clinical practice (2021)
The use of tocilizumab at a low dose is associated with lower secondary infections and mortality.